Business Wire

TRAKCEL

3.3.2021 14:02:10 CET | Business Wire | Press release

Share
TrakCel Fuels Growth and Increased Market Access Through Strategic Investment Round

TrakCel, a leading supplier of cellular orchestration solutions supporting the cell and gene therapy industry, today announces that it has closed its latest funding round led by AmerisourceBergen and Labcorp (NYSE: LH). These strategic investments enable further transformation of TrakCel’s cellular therapy orchestration solution, growth of its existing partner ecosystem, and continued global expansion.

The company will use both the investment and the combined expertise gained from collaborations with the investors to further augment its offering to both clinical and commercial-stage cell and gene therapy developers as part of its drive toward industry standardization and future innovation.

TrakCel has developed the broadest portfolio of live deployments in the industry across a range of therapies, from autologous and allogeneic therapies, personalized cancer vaccines and CRISPR, to tumor and marrow infiltrating lymphocyte therapies.

“The close of this funding delivers a unique opportunity to propel the improvement and evolution of our product and services portfolio in order to exceed expectations across the quickly evolving cell and gene therapy space,” said Ravi Nalliah, Chief Strategy Officer and Co-Founder, TrakCel. “In addition, this investment enhances our already considerable digital ecosystem of partners. Now, TrakCel has the funding and the partnership support to take advantage of our market and industry experience gained as the first orchestration solution to the cell and gene therapy marketplace.”

Augmenting and aligning its digital ecosystem with AmerisourceBergen in the future will allow TrakCel to significantly expand its reach. This will also enable the two companies to offer services that drive them toward further standardization of the delivery of cell and gene therapies.

“The advanced therapy sector is producing major advances in treatment that will revolutionize healthcare and the treatment of diseases with currently limited therapeutic options. It is essential that partners to manufacturers find ways to innovate on behalf of the patient and provider to enhance the treatment experience,” said Doug Cook, EVP, President of Commercialization and Animal Health at AmerisourceBergen. “By working with TrakCel, we’ll unlock new ideas and generate new value for all therapy participants, truly living our purpose of creating healthier futures.”

Labcorp, a leading global life sciences company, provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Labcorp’s mission to improve health and improve lives will be complemented and supported by TrakCel’s cell, gene and immunotherapy therapy software platform.

“The tools and technologies developed by TrakCel to support the critical needs of advanced therapy logistics are a good complement to the services that we supply for cell and gene therapies,” said Steve Anderson, PhD, Chief Scientific Officer, Labcorp Drug Development. “The ability to more effectively orchestrate those activities, paired with Labcorp’s deep scientific and clinical expertise, makes our collaboration an important aspect for the successful delivery and commercialization of advanced therapies. Our investment in TrakCel also further demonstrates our commitment to the area of precision medicine.”

End

About TrakCel

TrakCel is a market leading developer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining treatment collection to administration compliance and traceability. TrakCel is headquartered in Cardiff, Wales, UK, with US offices in California and New Jersey.
https://trakcel.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Charted Launches ERP-Native E-invoicing Across EMEA1.9.2026 14:30:00 CEST | Press release

Expansion will bring Charted E-invoicing across Europe, supporting accounts payable operations with a fully compliant invoicing process that remains embedded inside their ERP Charted, a leading accounts payable automation software and ERP services provider, today announced the expansion of Charted E-invoicing to support multiple countries spanning Europe, including Germany, France, Norway, Sweden, the Netherlands, Denmark and Finland. Further expansion to Italy, Romania, and Poland, will take place by the end of the quarter. These countries follow the official launch of Charted E-invoicing in Belgium, in May 2026. This expansion is designed to cement Charted support for users across EMEA, ensuring companies based in the region transacting on the PEPPOL network can remain compliant while keeping their accounts payable processes embedded inside their ERP. Charted E-invoicing works as a capability within Charted Invoice AI, to receive electronic invoices directly into the AP inbox, keepin

Riskified Expands its Risk Intelligence Platform with ARIA1.9.2026 14:00:00 CEST | Press release

AI Risk Intelligence Analyst (ARIA) gives fraud teams instant answers from their order data, helping them investigate patterns, drill into trends, and act on insights directly within the Riskified Control Center Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today expanded its risk intelligence platform with ARIA (AI Risk Intelligence Analyst), a conversational AI capability built directly into the Riskified Control Center. Fraud teams today have access to vast amounts of data, but solving urgent business questions often still requires exporting files, building reports, or waiting for additional analysis. ARIA changes that by letting merchants ask questions in natural language and get answers in seconds, complete with charts and tables that support the analysis. With direct access to Riskified metrics and their own business-specific reporting logic, ARIA can investigate and quickly answer a wide range of questions within an existing workflow

Vasion® Unlocks Windows PCs on Snapdragon Adoption with Native, Driverless Printing1.9.2026 14:00:00 CEST | Press release

Eliminating One of the Last Barriers to Enterprise Windows Modernization Vasion is removing a critical barrier to modern Windows device adoption with native, driverless printing for PCs powered by Snapdragon® compute processors. The Vasion Spring 2026 release delivers a seamless, cloud-native print experience, eliminating the need for printer drivers, emulation, or parallel print environments. The collaboration with Qualcomm Technologies combines the PC ecosystem reach of Snapdragon with Vasion's print automation expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901581087/en/ Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol (IPP) driverless printing support, enabling IT teams to modernize device fleets without disrupting operations or rearchitecting existing environments. Vasion fully supports Windows devices powered by Snapdragon with full Internet Printing Protocol

Perma-Pipe and Welspun Announce Memorandum of Understanding to Establish Pipe Manufacturing and Coating Facilities in Jordan1.9.2026 14:00:00 CEST | Press release

Strategic Partnership to Establish Integrated Pipe Manufacturing and Coating Capabilities to Support Water, Oil & Gas, and Infrastructure Projects in Jordan and the Levant Region. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a global leader in engineered pipe solutions specialising in anti-corrosion coatings, insulation solutions, containment systems, custom fabrication and leak detection, today announced that it has signed, together with Welspun Corp Limited (“Welspun”), a Memorandum of Understanding (“MOU”) with the developers of Jordan’s National Water Carrier Project and the Government of the Hashemite Kingdom of Jordan to advance the development of pipe manufacturing and advanced coating facilities in Jordan. The parties intend to establish a joint venture to support the development and operation of these facilities. Transaction Description Under the terms of the MOU, Perma-Pipe and Welspun have partnered to establish an integrated pipe m

Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 20261.9.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing The New Wave of Psychedelics” at 4:30pm ET. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resis

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye